Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Of 53,943 patients screened, 1,021 met inclusion criteria
We can dispense up to 12 weeks of medication at a time
EMA decision P/0336/2024 Paediatric Investigation Plan for Retatrutide
Chronic Conditions: Patients with conditions like sepsis or severe arrhythmias are closely monitored, as IV therapy may affect blood pressure and electrolyte levels
one Published Research The SURMOUNT and SURPASS trial programs provide extensive published documentation: SURMOUNT-1 through SURMOUNT-4: Obesity indication trials SURPASS-1 through SURPASS-5: Diabetes indication trials Extensive real-world evidence from post-marketing surveillance Published literature across multiple populations and demographics Retatrutide: GLP-1 + GIP + Glucagon Retatrutide represents the most comprehensive receptor coverage, activating all three pathways that Mazdutide and Tirzepatide divide between them
It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating
US$ 28.03
US$ 25.77
US$ 22.71
US$ 26.29
